Compare Gilead Sciences, Inc. (GILD) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Williams-Sonoma, Inc. — how do they compare? Gilead Sciences, Inc. trades at $136.56 (market cap $168.35B), while Williams-Sonoma, Inc. trades at $245.56 (market cap $29.51B). The key difference: Gilead Sciences, Inc. is far larger — about 5.7× Williams-Sonoma, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | WSM | |
|---|---|---|
Market Cap | $168.35B | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $251.81 |
52-Week Low | $110.56 | $168.64 |
Enterprise Value | $191.42B | $30.35B |
Dividend Yield | 2.42% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Williams-Sonoma (WSM) trades at $250.82, down 0.39% on the day, with strong profitability metrics including a 13.81% net income margin and 54.01% ROE. The stock shows a bullish technical trend, supported by moving averages, but RSI levels indicate overbought conditions. Recent earnings beats and a solid dividend history highlight operational strength, though valuation ratios like P/E of 28.09 suggest premium pricing. News coverage remains active, focusing on earnings potential and competitive positioning in the home furnishings sector.
WSM presents a mixed outlook: robust fundamentals and consistent earnings beats support upside, but high valuation and technical overbought signals pose near-term risks. Investor sentiment is cautiously optimistic, with a Moderate Buy analyst consensus and a $231.10 price target slightly below current levels. Key risks include consumer discretionary volatility and competitive pressures, while institutional interest and dividend payments offer stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
